Oral Session 3-13B MPN: Clinical (Prognosis)

[OS3-13B-1] Analysis of JAK2, CALR and MPL mutational status and treatment in myeloproliferative neoplasms

Koji Takaishi¹, Masahiro Takeuchi¹, Sachiho Aizeki¹, Shuntaro Isogai¹, Yuto Shioiri¹, Shinichiro Matsui¹, Asuka Shibamiya¹, Sanshiro Nakao¹, Arata Ishii¹, Yurie Nagai¹, Tatsuzo Mishina¹, Miki Yamazaki¹, Kensuke Kayamori¹, Kenji Kimura¹, Yutaro Hino¹, Nagisa Oshima¹, Shokichi Tsukamoto¹, Shio Mitsukawa^1,2, Yusuke Takeda¹, Naoya Mimura^1,2, Chikako Ohwada¹, Tohru Iseki^1,2, Ikumi Suzuki⁴, Hiroyuki Ebinuma⁴, Chiaki Nakaseko^1,3, Emiko Sakaida¹ (1.Department of Hematology, Chiba University Hospital, Chiba, Japan, 2.Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital, 3.Department of Hematology, International University of Health and Welfare, 4.Tsukuba Research Institute, Sekisui Medical Co.,Ltd, Ibaraki, Japan)